Xencor Presents Preclinical Data On XmAb942, A High-Potency Anti-TL1A Antibody For Inflammatory Bowel Diseases; Phase 1 Study In Healthy Volunteers Set To Begin In Q4 2024, With Initial Data Expected In First Half Of 2025
Portfolio Pulse from Benzinga Newsdesk
Xencor has presented preclinical data on XmAb942, a high-potency anti-TL1A antibody aimed at treating inflammatory bowel diseases. A Phase 1 study in healthy volunteers is scheduled to start in Q4 2024, with initial data expected in the first half of 2025.
October 10, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xencor has announced preclinical data for XmAb942, an antibody for inflammatory bowel diseases, with Phase 1 trials set for late 2024. This development could enhance Xencor's pipeline and future revenue potential.
The announcement of preclinical data and upcoming Phase 1 trials for XmAb942 is a positive development for Xencor, indicating progress in their drug pipeline. This could lead to increased investor interest and potential future revenue if the trials are successful.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100